Israel Englander Exelixis, Inc. Transaction History

Millennium Management LLC

$207 Billion
Q2 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Exelixis, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 385,686 shares of EXEL stock, worth $13.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

385,686

Previous 230,979 66.98%

Holding current value

$13.7 Million

Previous $5.48 Million 58.11%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$20.34 - $23.73 $3.15 Million - $3.67 Million	154,707 Added 66.98%	385,686 $8.67 Million
Q1 2024 May 15, 2024	SELL	$20.17 - $23.93 $25.3 Million - $30 Million	-1,252,193 Reduced 84.43%	230,979 $5.48 Million
Q4 2023 Feb 14, 2024	SELL	$19.25 - $24.13 $3.48 Million - $4.36 Million	-180,816 Reduced 10.87%	1,483,172 $35.6 Million
Q2 2023 Aug 14, 2023	BUY	$18.17 - $20.48 $27.4 Million - $30.9 Million	1,506,354 Added 955.6%	1,663,988 $31.8 Million
Q1 2023 May 15, 2023	BUY	$16.3 - $19.41 $1.13 Million - $1.35 Million	69,378 Added 78.61%	157,634 $3.06 Million
Q4 2022 Feb 14, 2023	SELL	$14.96 - $17.39 $18.8 Million - $21.9 Million	-1,259,623 Reduced 93.45%	88,256 $1.42 Million
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $5.98 Million - $8.49 Million	381,334 Added 39.45%	1,347,879 $21.1 Million
Q2 2022 Aug 15, 2022	BUY	$17.44 - $23.16 $9.66 Million - $12.8 Million	553,905 Added 134.23%	966,545 $20.1 Million
Q1 2022 May 16, 2022	SELL	$17.03 - $22.67 $1.7 Million - $2.27 Million	-99,969 Reduced 19.5%	412,640 $9.36 Million
Q4 2021 Feb 14, 2022	BUY	$15.84 - $21.88 $1.95 Million - $2.7 Million	123,212 Added 31.64%	512,609 $9.37 Million
Q3 2021 Nov 15, 2021	BUY	$16.3 - $21.14 $1.94 Million - $2.52 Million	119,112 Added 44.07%	389,397 $8.23 Million
Q2 2021 Aug 16, 2021	SELL	$17.95 - $25.56 $9.67 Million - $13.8 Million	-538,901 Reduced 66.6%	270,285 $4.93 Million
Q1 2021 May 17, 2021	BUY	$20.53 - $25.22 $13.2 Million - $16.3 Million	644,560 Added 391.53%	809,186 $18.3 Million
Q4 2020 Feb 16, 2021	BUY	$18.39 - $24.8 $1.94 Million - $2.62 Million	105,591 Added 178.86%	164,626 $3.3 Million
Q3 2020 Nov 16, 2020	SELL	$20.67 - $26.94 $3.84 Million - $5 Million	-185,537 Reduced 75.86%	59,035 $1.44 Million
Q2 2020 Aug 14, 2020	SELL	$16.46 - $27.42 $8.9 Million - $14.8 Million	-540,451 Reduced 68.85%	244,572 $5.81 Million
Q1 2020 May 14, 2020	BUY	$14.46 - $21.8 $1.51 Million - $2.28 Million	104,475 Added 15.35%	785,023 $13.5 Million
Q4 2019 Feb 14, 2020	BUY	$15.15 - $18.89 $2.52 Million - $3.14 Million	166,229 Added 32.32%	680,548 $12 Million
Q3 2019 Nov 14, 2019	BUY	$17.68 - $22.65 $6 Million - $7.68 Million	339,285 Added 193.84%	514,319 $9.1 Million
Q2 2019 Aug 14, 2019	BUY	$18.93 - $24.75 $1.45 Million - $1.89 Million	76,558 Added 77.74%	175,034 $3.74 Million
Q1 2019 May 14, 2019	SELL	$19.6 - $24.76 $27 Million - $34.1 Million	-1,375,849 Reduced 93.32%	98,476 $2.34 Million
Q4 2018 Feb 14, 2019	SELL	$13.65 - $21.8 $9.94 Million - $15.9 Million	-728,515 Reduced 33.07%	1,474,325 $29 Million
Q3 2018 Nov 14, 2018	BUY	$15.87 - $22.4 $26.3 Million - $37.2 Million	1,659,077 Added 305.11%	2,202,840 $39 Million
Q2 2018 Aug 14, 2018	SELL	$18.56 - $22.45 $7.15 Million - $8.65 Million	-385,107 Reduced 41.46%	543,763 $11.7 Million
Q1 2018 May 15, 2018	SELL	$22.15 - $31.89 $5.11 Million - $7.36 Million	-230,918 Reduced 19.91%	928,870 $20.6 Million
Q4 2017 Feb 14, 2018	SELL	$24.23 - $30.93 $7.38 Million - $9.42 Million	-304,630 Reduced 20.8%	1,159,788 $35.3 Million
Q3 2017 Nov 14, 2017	BUY	$23.35 - $29.24 $34.2 Million - $42.8 Million	1,464,418	1,464,418 $35.5 Million

Others Institutions Holding EXEL

# of Institutions

468

Shares Held

240M

Call Options Held

2.04M

Put Options Held

1.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.4B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account